Critical flicker fusion threshold: a potentially useful measure for the early detection of Alzheimer's disease

Abstract

Critical Flicker Fusion Threshold (CFFT) is a psychophysical threshold and, in psychological terms, it is regarded as a measure of information processing capacity. CFFT has previously been shown to be a valid and reliable measure in young healthy volunteers and it also has a long history of use as a psychopharmacological measure in this group. Furthermore, the test satisfies many of the requirements of an 'ideal' measure for monitoring change, especially in a psychopharmacological context. Despite this, CFFT has been neglected as a research tool in elderly and Alzheimer's disease (AD) populations and was therefore investigated further in this regard. CFFT in community-based healthy elderly subjects was normally distributed, but CFFT and ascending and descending thresholds were not significantly correlated with age. The difference between ascending and descending thresholds was, however, significantly correlated with age and this relationship appeared to be due almost entirely to a change in the descending threshold. In addition, descending thresholds were found to be significantly greater than ascending thresholds in healthy elderly subjects. In contrast, patients with AD were found to have significantly lower CFFT and descending scores compared with healthy elderly subjects. Interestingly, descending thresholds were significantly lower than ascending thresholds in the patient group, a feature that may be a characteristic of AD. Mean CFFT and ascending and descending thresholds were found to have a high test-retest, split-half and inter-rater reliability, in addition to being significantly correlated with a number of psychometric measures, clinical scales and neuropsychological instruments commonly used to assess patients with AD. CFFT is a quick and simple measure to administer and patients had no difficulty completing the test. Because the measure is a psychophysical threshold, it is free from educational and cultural bias and there are no floor or ceiling effects. From the results of this work, CFFT appears to be a useful research tool in AD. It may be a suitable measure for monitoring cognitive change over time, either in community studies of AD or a clinical trial context, but further work is required. The technique might also contribute to the early detection of AD. This application would be particularly important because it would enable effective pharmacotherapies to be started early during the course of the illness before neuronal damage is too advanced and this would have significant benefits for patients. Copyright 2000 John Wiley & Sons, Ltd.

A randomized placebo-controlled study on the effects of lutein and zeaxanthin on visual processing speed in young healthy subjects

“…These empirical data are consistent with the idea that increasing central levels of xanthophyllic carotenoids can have a generally positive effect upon brain function. We define this as salubrious based on the observation that aging [26] and degenerative disease (e.g., Alzheimer's; [7]; minimal hepatic encephalopathy; [25]; Multiple Sclerosis; [8]) tend to disproportionately affect (i.e., slow) temporal processing. Faster visual processing tends to be positively correlated with, for example, improved sports performance [12] and driver safety [20], reading speed [14], and executive cognitive function [1].…”

A double-blind, placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers

“…The mean of the eight thresholds gives the critical flickerfusion frequency in hertz. CFF has been shown to be sensitive both to changes in cognitive status (Curran and Wattis 2000) and to the effects of a wide range of psychoactive compounds in both volunteers (Hindmarch 1975(Hindmarch , 1982(Hindmarch , 1994 and patients (Fairweather et al 1993b;1999). A lowering of the threshold is indicative of a reduction in the overall integrity of the CNS.…”

Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy

“…HE and CHE are associated with decreased quality of life, impaired working performance, and patients become unfit to safely drive motor vehicles [16][17][18][19][20][21] .…”